Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
26 Luglio 2024 - 3:00PM
Boston (July 26, 2024)—Allarity Therapeutics,
Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2
clinical-stage pharmaceutical company dedicated to developing
personalized cancer treatments, announced that its Board of
Directors has decided to postpone the Annual Meeting of
Stockholders, which was originally scheduled for 10:00 AM Eastern
Time today, July 26, 2024.
On July 25, 2024, the Board, exercising its authority under the
Company’s bylaws, opted to delay the meeting to a future date,
which will be determined and announced in due course.
The Company will provide updated information regarding the new
date for the Annual Meeting and, if necessary, a new record date,
as soon as it becomes available.
About Allarity TherapeuticsAllarity
Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage
biopharmaceutical company dedicated to developing personalized
cancer treatments. The Company is focused on development of
stenoparib, a novel PARP/Tankyrase inhibitor for advanced ovarian
cancer patients, using its DRP® companion diagnostic for patient
selection in the ongoing phase 2 clinical trial, NCT03878849.
Allarity is headquartered in the U.S., with a research facility in
Denmark, and is committed to addressing significant unmet medical
needs in cancer treatment. For more information, visit
www.allarity.com.
Follow Allarity on Social MediaLinkedIn:
https://www.linkedin.com/company/allaritytx/X:
https://twitter.com/allaritytx
Forward-Looking Statements This press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements provide the Company’s current expectations or forecasts
of future events. The words “anticipates,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,”
“possible,” “potential,” “predicts,” “project,” “should,” “would”
and similar expressions may identify forward-looking statements,
but the absence of these words does not mean that a statement is
not forward-looking. These forward-looking statements include, but
are not limited to, statements regarding the Company's plans to
announce a new date for the postponed Annual Meeting of
Stockholders and the timing of related updates. Any forward-looking
statements in this press release are based on management’s current
expectations of future events and are subject to multiple risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, the potential impact of the postponement of
the Annual Meeting on stockholder engagement and decision-making,
and the Company’s ability to provide timely updates on the
rescheduled meeting and any new record date. For a discussion of
other risks and uncertainties, and other important factors, any of
which could cause our actual results to differ from those contained
in the forward-looking statements, see the section entitled “Risk
Factors” in our Form S-1 registration statement filed on April 17,
2024, and our Form 10-K annual report on file with the Securities
and Exchange Commission (the “SEC”), available at the SEC’s website
at www.sec.gov, and as well as discussions of potential risks,
uncertainties and other important factors in the Company’s
subsequent filings with the SEC. All information in this press
release is as of the date of the release, and the Company
undertakes no duty to update this information unless required by
law.
###
Company Contact:
investorrelations@allarity.com
Media
Contact: Thomas
Pedersen Carrotize
PR &
Communications +45
6062 9390 tsp@carrotize.com
- Allarity Press Release - Stockholder Meeting Postponed
Grafico Azioni Allarity Therapeutics (NASDAQ:ALLR)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Allarity Therapeutics (NASDAQ:ALLR)
Storico
Da Dic 2023 a Dic 2024
